CD8A and neoplasm: Taking into account that Avelumab treatment in combination with IL-2 or IL-15 may result in tumor cells being exposed to higher levels of IFN-γ derived from NK cells or CD8 T cells (41); we further studied in vitro the effect of combining both treatments.